Skip to main content

Exosystems

Category: AI in Healthcare

An AI-powered digital healthcare platform providing neuromuscular diagnosis and personalized rehabilitation solutions using wearable sensors and proprietary digital biomarkers. Exosystems was founded in 2017. The company is led by Hoo-man Lee. Based in Seongnam, South Korea. Team size: 10-50. Total funding raised: $5.5M. Latest round: Series A. Key investors include SBI Investment, Kakao Ventures, Laguna Investment, SparkLabs Global Ventures, Korea Technology Finance Corporation (Kibo).

Founded
2017
Headquarters
Seongnam, South Korea
Team size
10-50
Total funding
$5.5M

Value proposition

Transforming neuromuscular care from subjective assessments to data-driven medicine by providing objective muscle health scoring and personalized, gamified home-rehabilitation.

Products and solutions

exoRehab: A wearable rehabilitation device providing Neuromuscular Electrical Stimulation (NMES) and exercise monitoring., M-STAMP: A lightweight, wearable sensor for high-fidelity neuromuscular signal (sEMG) acquisition., EXOMed-DeepSarc: AI-driven software for the screening and diagnostic assistance of sarcopenia (muscle loss)., Muscle Function Index (MFI): A proprietary AI digital biomarker used to quantify muscle quality and neuromuscular connectivity.

Unique value

Developed the 'Muscle Function Index (MFI)', a unique digital biomarker that uses surface EMG (sEMG) to provide clinical-grade muscle health scores without the need for expensive imaging like DXA or CT scans.

Target customer

Medical professionals in rehabilitation and orthopedics, elderly care facilities, post-surgery patients, and clinical research institutions.

Industries served

Digital Health, Medical Devices, Artificial Intelligence, Rehabilitation Robotics, Elderly Care (AgedTech)

Technology advantage

Combines medical-grade wearable hardware with proprietary AI algorithms that analyze neuromuscular signals in real-time, allowing for both diagnosis (Sarcopenia) and intervention (NMES-based rehab) in a single ecosystem.

How they differentiate

Focuses on 'Muscle Function Index (MFI)'—a proprietary AI digital biomarker that analyzes neuromuscular signals (sEMG) to quantify muscle quality and connectivity. Unlike competitors focused primarily on mechanical joint movement, Exosystems integrates diagnostic screening for sarcopenia with personalized electrical stimulation (NMES) in a single wearable ecosystem.

Main competitors

Neofect, H-Robotics, Angel Robotics, Kaia Health

Key partnerships

Daewoong Pharmaceutical & Seers Technology: Partnership for 'Smart Ward' integrated solutions to monitor and diagnose patients in hospital settings., Bundang Seoul National University Hospital: Long-term clinical R&D partner for validating digital biomarkers., Medipeace: International NGO partner for global healthcare expansion (e.g., Vietnam market).

Notable customers

Bundang Seoul National University Hospital, Daewoong Pharmaceutical, Seers Technology, Medipeace (International NGO)

Major milestones

Founded in Jan 2017 as a spin-off from the Electronics and Telecommunications Research Institute (ETRI), Received CES 2020 Innovation Award for 'exoRehab', Secured 4.5B KRW Series A funding in Oct 2021, Received CES 2024 Innovation Award for AI-based Digital Biomarker Solution, Designated as an 'Innovative Medical Device' by the Korean Ministry of Food and Drug Safety (MFDS) for DeepSarc AI in Nov 2024

Growth metrics

Maintains a workforce of approximately 19 employees and has successfully advanced from a hardware-focused robotics startup to an AI software-driven digital biomarker platform.

Market positioning

Neuromuscular digital healthcare platform specializing in AI-driven muscle health diagnostics and remote rehabilitation.

Geographic focus

South Korea (HQ), Southeast Asia (Vietnam), and North America (CES recognition and global clinical R&D).

Patents and IP

Holds multiple patents regarding AI-based neuromuscular evaluation and biosignal processing; research published in international journals such as IEEE-TNSRE and JAMDA.

About Hoo-man Lee

Hoo-man Lee is the Founder and CEO of Exosystems. He spent over 7 years as a senior researcher at the Electronics and Telecommunications Research Institute (ETRI) in the Intelligent Robot System Research Group. He specializes in wearable robotics and AI-driven healthcare solutions. He holds a Ph.D. in Convergence Science (Robotics) from Seoul National University.

Official website: